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Introduction 21 
Distal humerus fractures represent about 1-2% of adult fractures and about 10% of humeral 22 
fractures. [1] The injury has a bimodal distribution with a peak incidence in young males 23 
secondary to high energy trauma and a second peak in osteoporotic elderly (typically female) 24 
patients over the age of 60 years. [2] It is predicted that the annual rate of distal humeral 25 
fractures in the elderly population is likely to triple by 2030 due to an increasingly aging 26 
population structure. [3] These fractures typically require surgical treatment as non-operative 27 
treatment is associated with a high frequency of complications such as non-union, malunion, 28 
stiffness and pain - any of which can lead to severe functional deficit and a subsequent loss of 29 
independence due to an inability to perform activities of daily living. [4-9] It is for this reason 30 
that non-operative management is typically only advocated for those patients who are unfit 31 
for anaesthesia and surgery. [10] 32 
The AO classification of distal humeral fractures defines Type C injuries as comminuted 33 
intra-articular fractures [11] and these injuries provide a significant surgical challenge. The 34 
choice of surgical intervention is controversial and forms the basis of this meta-analysis. 35 
Surgical options include open reduction and internal fixation (ORIF), which in the 36 
contemporary literature is most frequently performed with either orthogonal or parallel 37 
plating according to AO principles. [12, 13] However, osteoporotic bone and highly 38 
comminuted fracture patterns often preclude anatomic reduction and early mobilisation, and 39 
predispose to failure of fixation, revision surgery, stiffness and a high rate of functional 40 
limitation (though still preferable to non-operative treatment). An alternative surgical option 41 
is total elbow arthroplasty (TEA). However, this strategy is also associated with a risk of 42 
complications such as infection, dislocation, peri-prosthetic fracture, nerve palsy, skin 43 
complications and revision for other causes. [14-16]   44 
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Although the literature has previously compared ORIF versus TEA there remains a lack of 45 
consensus regarding the optimum treatment choice. The aim of this meta-analysis was to 46 
determine which procedure provided superior clinical outcomes for elderly patients with 47 
distal humeral fractures. 48 
 49 
Methods 50 
A systematic review of the literature was conducted in accordance with the PRISMA 51 
guidelines [17] using the online databases Medline and EMBASE. The searches were 52 
performed independently by two authors on the 1st September 2016 and repeated on the 12th 53 
September 2016 to ensure accuracy. The Medline search strategy is illustrated in Table I. 54 
We included only studies that were published in English. Both cases series and comparative 55 
studies reporting outcomes after TEA and ORIF in patients aged 60 years and above with an 56 
acute distal humerus fracture were included. Studies reporting outcomes of patients with a co-57 
existent diagnosis of rheumatoid arthritis were included. The TEA could be of any design via 58 
any approach and the ORIF group could include any type of plate fixation via any approach. 59 
The study must have reported either a functional outcome measure or associated 60 
complications. Studies were excluded if participants included chronic injuries, non-unions or 61 
cases of failed plate fixation. In addition, only primary research was considered for review 62 
with any abstracts, comments, review articles and technique articles excluded. 63 
The studies were appraised independently by two authors using a validated quality 64 
assessment scale for non-controlled study, [18] STROBE checklist [19] for comparative studies 65 
and the CONSORT statement for randomised controlled trials (RCT). [20]  66 
 67 
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Statistical methods 68 
Results were pooled from different studies using meta-analysis techniques. If the required 69 
data was not provided in the original article, the corresponding author of the respective article 70 
was contacted to request these. Patient related outcome measures were only included in the 71 
meta-analysis if they were reported in at least two studies. Data regarding complications and 72 
revision surgery was also included.  73 
Two main sets of analyses were performed. The first set of analyses compared TEA and 74 
ORIF using results from the comparative studies only. Four outcomes were used for 75 
comparisons; the Mayo Elbow Performance Score (MEPs), the Disability of Arm, Shoulder 76 
and Hand score (DASH), complications and re-interventions. MEPS and DASH scores are 77 
continuous and their differences in means were pooled assuming they are normally 78 
distributed. The complications and re-interventions reported as binary and percentage 79 
differences from identified studies were pooled. For the second set of analyses, TEA and 80 
ORIF were compared using results from both comparative studies and case series. In order to 81 
include data from case series as well from comparative studies, data from the TEA and ORIF 82 
arms were pooled separately. The means for MEPS and DASH scores were pooled assuming 83 
they were normally distributed. Complication and re-intervention rates were pooled assuming 84 
the number of complications and revisions were distributed binomially. The packages “meta” 85 
and “metaphor” in the R statistical program were used to perform these calculations. In both 86 
sets of analyses, a random-effects meta-analysis was used because it was believed that studies 87 
have inherent differences. 88 
 89 
 90 
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Results 92 
The search strategy identified 27 studies eligible for inclusion; one randomised controlled 93 
trial, [21]   four comparative studies, [22-25] 14 ORIF cases series [26-39]  and 8 TEA case series. 94 
[40-47] A flow chart of the search strategy is shown in Figure I. The total number of 95 
participants in all studies was 1307; comparative studies (n=330), ORIF case series (n=777) 96 
and TEA case series (n=200). Concise details of included studies are given in Table II to V. 97 
 98 
Comparative Studies 99 
Of the five studies included, one was a randomised controlled trial providing level I evidence 100 
and the remaining four were level III retrospective comparative studies. The lack of 101 
randomisation in the retrospective comparative studies risks selection bias, and the failure to 102 
define a primary outcome measure or inclusion of a power calculation reduces the strength of 103 
these studies further. The study quality varied as demonstrated by the wide-ranging 104 
adherence to the STROBE checklist and CONSORT statement (Table VI and VII). 105 
McKee et al. [21] performed a multi-centre randomised controlled trial of 40 patients which 106 
provided the highest level of evidence reviewed. The authors reported a statistically 107 
significant improvement in MEPS at every time point up to 2 years (p=0.015) and in the 108 
DASH (p=0.04) up until six months in the TEA group. However, the study failed to 109 
demonstrate a statistically significant difference in complication rate (p=0.40) which was the 110 
study’s defined primary outcome measure. A limitation of this study is the use of a 111 
combination of locking and non-locking plates in the ORIF treatment arm. It is clear from the 112 
contemporary literature that locking plates confer a significant biomechanical advantage and 113 
therefore the use of non-locking plates could be considered a possible confounder  [23, 24] that 114 
may potentially have resulted in poorer outcomes in the ORIF group. The power calculation 115 
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was based on the intention to detect a 40% difference in reoperation rates, however a lower 116 
rate of reoperation would be an important clinical difference to distinguish, and therefore the 117 
high rate set has the potential to result in an under powered study. In addition, during the 118 
study 5 patients originally allocated to the ORIF group were transferred to the TEA group at 119 
the time of surgery as the surgeon deemed the fracture to be unfixable. This cross-over of 120 
these patients has the potential to unbalance the two groups by concentrating patients with 121 
more complex fractures within the TEA group. Patients with more complex fractures may 122 
have additional known and unknown confounding factors that may independently affect 123 
outcomes.  124 
Ellwein et al. [23] retrospectively reviewed 29 patients, of whom 19 were in the subgroup over 125 
the age of 60 years included in the meta-analysis. The authors reported that those undergoing 126 
TEA had improved functional outcomes, DASH (p=0.023) and MEPS (p=0.078), and a 4.4 127 
times lower risk of a major complication (95% CI 0.65-29.30). However, the study has 128 
limitations that include variations in characteristics between the two groups (ORIF group had 129 
a lower mean age, higher proportion of male patients and less severe fracture patterns), lack 130 
of details regarding reasons for treatment allocation and a variable length of follow up. The 131 
described difference in study populations may reflect true clinical practice as young male 132 
patients are deemed a relative contraindication to TEA due to the lifetime restrictions in 133 
function and concern regarding longevity of the implants. 134 
Frankle et al. and Egol et al. [22, 24] performed retrospective comparative studies and 135 
demonstrated comparable results between the treatment modalities. Common limitations 136 
included the absence of randomisation, lack of clarity over the treatment allocation process 137 
and variation in patient characteristics. In addition, Frankle et al. [22] reported only female 138 
patients and 67% of patients in the TEA group suffered from rheumatoid arthritis compared 139 
to 0% in the ORIF group. Obert et al. [25] report a combination of a retrospective review 140 
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(n=410) and prospective study (n=87) focused on the complication rate associated with these 141 
procedures. Despite showing a higher complication rate after ORIF (44% versus 23%), the 142 
failure of the paper to describe further patient characteristics, surgical technique and 143 
functional outcome limits the information that can be obtained from this study. 144 
 145 
 146 
Meta-analysis of comparative studies 147 
Functional outcomes 148 
There were three eligible studies that compared TEA to ORIF using the MEPS score, [21-23]  149 
and the results of the meta-analysis for this outcome are presented in Figure II. In all studies, 150 
the mean MEPS score for TEA patients was greater than for ORIF patients. The pooled mean 151 
difference is 13.1 (95% CI 9 to 17) indicating TEA is associated with better outcomes with 152 
respect to MEPS. Two of the included studies compared TEA versus ORIF using the DASH 153 
score. [21, 23]  The results of the meta-analysis are summarised in Figure III. In both studies, 154 
the mean DASH scores for TEA patients was superior to the mean DASH scores for ORIF 155 
patients. The pooled mean difference is 14.2 (95% CI 4 to 22) indicating TEA is statistically 156 
better than ORIF with respect to DASH. 157 
 158 
Complications 159 
Four of the included studies compared the complication profiles of TEA verses ORIF. [21-23, 160 
25]  Figure IV summarises the results for the meta-analysis of percentage complications 161 
differences. In all studies complications were higher in the ORIF group. The pooled 162 
percentage complications difference was 21 (95% CI 12 to 29) indicating TEA was 163 
associated with fewer complications than ORIF.  164 
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Re-interventions 165 
Two studies compared the need for re-intervention after TEA and ORIF. The results are 166 
conflicting with McKee et al. [21] reporting a lower re-intervention rate with TEA and Egol et 167 
al. [24] the opposite (Figure V). Meta-analysis of the data from these two studies showed that 168 
the pooled percentage re-intervention difference is -8 (95% CI -29 to 13) suggesting that TEA 169 
is associated with lower risk of re-intervention than ORIF but the difference is not 170 
statistically significant.  171 
 172 
To summarise, TEA is statistically superior to ORIF based on three outcomes (MEPS score, 173 
DASH score and complications) but not in terms of revision rate. 174 
 175 
 176 
Case Series 177 
In total 22 case series were reviewed, 14 ORIF cases series [26-39] and 8 TEA case series. [40-47] 178 
The size of the studies varied from 7 to 342 participants. 777 patients with a mean age of 77.8 179 
years were analysed in the ORIF case series and 200 patients with a mean age of 75.7 years 180 
in the TEA case series. These studies provide only level IV evidence and hence have 181 
significant limitations that must be taken into account when interpreting the pooled data. The 182 
study quality varied as demonstrated by the wide-ranging adherence to the Rangel criteria 183 
(Table VIII and IX).  Significant heterogeneity was encountered in study methodology that 184 
included treatment allocation, fracture pattern, surgical approach, type of implants and length 185 
of follow up. 186 
 187 
 188 
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Single arm meta-analysis 189 
Functional Outcomes 190 
Three comparative studies [21-23] and seven TEA case series [40-42, 44-47]  reported MEPS score 191 
and the meta-analysis is shown in Figure VI. The pooled mean MEPS score from the ten 192 
TEA studies is 91.5 (95% CI = 88-95). Three comparative studies [21-23] and three ORIF case 193 
series [28, 38, 39] reported MEPS, the meta-analysis is shown in Figure VII. The pooled mean 194 
from the six studies is 82.8 (95% CI = 77-89). The 95% confidence intervals for MEPS in the 195 
TEA (88-95) and ORIF (77-89) groups overlap and therefore this difference is not 196 
statistically significant.  197 
 198 
Complications 199 
Eleven studies; seven case series [40-44, 46, 47] and four comparative studies [40-42, 44], reported 200 
complications for TEA (Figure VIII). The pooled percentage of complications in all eleven 201 
studies is 25% (95% CI = 19-32). Seventeen studies, thirteen case series [26-32, 34-39] and four 202 
comparative studies, [21-23, 25] reported complications for ORIF (Figure IX).  The pooled 203 
percentage of complications in all seventeen studies is 34% (95% CI = 28-42). The 95% 204 
confidence intervals for complications in TEA (19-32%) and ORIF (28-42%) overlapped 205 
meaning the difference is not statistically significant.  206 
 207 
Re-intervention rates 208 
Two cases series [41, 42] and two comparative studies [21, 24] reported re-intervention rates for 209 
TEA. The pooled percentage of re-interventions for these four studies is 20% (95% CI = 14-210 
28). Four cases series [26, 31-33] and two comparative studies [21, 24] reported re-intervention 211 
rates for ORIF. The pooled percentage of re-interventions for these six studies is 15% (95% 212 
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CI = 8-25). Overlapping of the confidence intervals suggests the difference in re-intervention 213 
rates for TEA and ORIF is not statistically significant.  214 
 215 
 216 
Discussion 217 
Meta-analysis of data from the included comparative studies has demonstrated that TEA is 218 
associated with superior outcomes with respect to MEPS, DASH and frequency of 219 
complications when compared to ORIF and that these findings are statistically significant. 220 
The pooled mean differences between TEA and ORIF of 13.1 for MEPS and 14.2 for DASH 221 
are higher than the recognised minimal clinically important differences for these metrics (10 222 
for MEPS and 7-10 for DASH). [48-50] The only level 1 evidence from McKee et al. [21] also 223 
reported a statistically significant improvement in functional outcome after TEA with 224 
excellent or good outcomes according to the MEPS in 84% of TEA patients compared to 225 
53% in the ORIF group. ORIF was associated with a 21% (95% CI 12 to 29) pooled increase 226 
in complications compared to TEA. These results demonstrate that TEA is associated with 227 
clinically superior outcomes with fewer complications when compared to ORIF. 228 
Inclusion of five studies for the comparative meta-analysis resulted in 330 patients being 229 
available for analysis. Although combination of data increases the power of a meta-analysis, 230 
the low availability of studies still risks under powering. The RCT from McKee et al. [21] was 231 
conducting in keeping with the CONSORT statement providing high quality level I evidence. 232 
The four comparative studies were appraised against the STROBE statement which provides 233 
22 criteria to assess the quality of the study against. The number of criteria met varied from 7 234 
to 20 demonstrating that the quality of the evidence varied. Common weaknesses included 235 
the limited information provided on the methods of recording data, techniques used to 236 
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minimise bias, study limitations and statistical tests used. Obert et al. [25] only achieved 7 of 237 
the 22 criteria. Although the authors provided important data on risk of complications the 238 
limited information on sample selection, data collection, patient demographics and functional 239 
outcomes limits the strength of their results.  240 
When single arm meta-analysis was performed for all studies, including comparative studies 241 
and case series, any differences in outcomes did not reach statistical significance. The failure 242 
of this part of the analysis to demonstrate significant results may be explained by the need to 243 
compute 95% confidence intervals for TEA and ORIF separately, which is more conservative 244 
estimate than calculating the confidence intervals for the difference in comparative studies. 245 
Furthermore, the inclusion of non-comparative studies increases the risk of bias and 246 
confounding. 247 
Despite the meta-analysis of comparative studies demonstrating that TEA had a lower 248 
complication rate than ORIF, this analysis does not take into account the severity of the 249 
complication and the impact of the complications on patients. When performing arthroplasty, 250 
it is necessary to take into account the survivorship of the implant and the burden of any 251 
salvage procedures on the patient. The risk of TEA failure, in the form of component 252 
loosening, osteolysis or bushing failure, are all more likely after 5 years and this was not 253 
assessed in the included studies. The longevity of TEA in fracture patients has only recently 254 
been explored, Prasad et al. analysed 37 TEA non-rheumatoid trauma patients and reported 255 
implant survivorship of 89.5% at ten years. The study also showed that at ten years only 53% 256 
of the original cohort were alive, highlighting the typical patient demographic selected for 257 
TEA. [51] An attempt was made to compare the rate of re-intervention following the two 258 
procedures, however only two of the five included studies reported this outcome, their results 259 
were contradictory and the length of follow up in these studies was only 24 months. This 260 
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highlights the need for long-term comparative studies with explicit reporting of complications 261 
and re-operations.  262 
Although this meta-analysis has shown an improved functional outcome and lower rate of 263 
complications after TEA in comparative studies, it is important to highlight that these 264 
findings should not be generalised to younger patients. Patients included in TEA groups had a 265 
trend to more complex fracture patterns as selection bias resulted in simpler fractures entering 266 
the ORIF groups. Therefore the role of TEA in a subgroup of younger patients (60-70 years) 267 
with less complex fractures perhaps provide the greatest clinical conundrum, where the 268 
survivorship and functional limitations of TEA must be balanced against the risks of ORIF. It 269 
is important to note that the lack of significant difference between the groups with respect to 270 
revision and complication rates should be interpreted with caution due to this selection bias 271 
and further randomised controlled study is appropriate to more clearly define the roles of 272 
each procedure in management of type C distal humerus fractures particularly in this sub-273 
cohort of younger patients. 274 
Alternative treatment options for distal humeral fractures are available that have not been 275 
included in this meta-analysis. Two recent retrospective studies report modest results when 276 
treating low-demand or medically unfit patients non-operatively. [10, 52] Both papers conclude 277 
that that non-operative treatment can be considered in these patient categories in order to 278 
avoid the risks of surgery whilst TEA can still be used as a salvage procedure if non-279 
operative treatment fails. [10, 52] Hemiarthroplasty of the distal humerus is another surgical 280 
option that is gaining in popularity. A recent study reported at a mean of 3 years follow up 281 
that the functional outcomes were a mean MEPS score of 90 and a mean DASH score of 20, 282 
a complication rate of 19% and a 12% rate of revision surgery. [53] Further work and research 283 
is required to fully delineate the role of these different surgical options in these fractures and 284 
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assess whether there are further subgroups who would particularly benefit from the differing 285 
surgical techniques. 286 
The small number of comparative studies available meant case series were also evaluated to 287 
increase the data available for analysis. The inclusion of this lower quality evidence increases 288 
the risk of introducing bias into the results with the main limitations being the lack of a 289 
comparative group and randomisation. The case series were appraised against Rangel’s 290 
criteria which showed a wide variation in quality; this system includes 16 criteria to measure 291 
quality with scores ranging from 6 to 15. Common themes of study limitation included 292 
restricted information on the surgeons carrying out the procedure, the peri-operative care, the 293 
handling of missing data and the details regarding patient selection. These weaknesses were 294 
mitigated to some extent by performing statistical analyses on comparative and non-295 
comparative studies separately. However, the failure of the non-comparative part of the meta-296 
analysis to demonstrate any significant differences between groups may actually be as a 297 
result of the lower quality evidence and the variation in study quality. Therefore the ability of 298 
the comparative studies, which provide more robust evidence, to demonstrate statistically 299 
significant improvements after TEA form the basis for the studies conclusion. 300 
 301 
Conclusion 302 
Meta-analysis of comparative studies demonstrates that TEA is associated with statistically 303 
significant and clinically superior MEPS and DASH when compared to ORIF in elderly 304 
patients.  305 
 306 
 307 
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